Biotech Values

[microcapfun]

>>I think the reason nothing has yet superseded Sustiva is that it’s a tall order to develop a drug which is qD and is effective at a low enough dose to enable safe and tolerable co-administration (ideally co-formulation) with Truvada. Not that many companies have the expertise to do it.<<

Much of the team which designed Sustiva is still intact - but at Incyte, rather than Dupont Pharma. At Incyte they have put together an impressive pipeline in a relatively short time. They seem to have some of the best medicinal chemists anywhere.

micro